# Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

> **NCT03322540** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 154 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Epacadostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03322540
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2019-01-10
- **Final completion:** 2020-11-09
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322540, "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03322540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*